Armelle Logié - Concepedia

Author

Armelle Logié

AstraZeneca (United Kingdom)

Also Known As

A LOGIE, A Logie, A Logié, A. Logie, A. Logié, AW Logie, Armelle Logie, Armelle Logié, Armelle Logié, Diane Law

Publications

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)Inserm Hôpital Armand-Trousseau Sorbonne Université Hôpital Cochin

About

Armelle Logié is an author at AstraZeneca (United Kingdom) specializing in medicine, cancer research, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	389
2	Cell Biology	5	5	294
3	Endocrinology	2	2	89
4	Health Sciences	1	1	32
5	Biochemistry	1	1	13

Armelle Logié

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action <i>in vivo</i> , pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models Barry R. Davies, Armelle Logié, Jennifer S. McKay, Molecular Cancer Therapeutics	2007	387
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 Tim P. Green, Mike Fennell, Robin Whittaker, Molecular Oncology	2009	254
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans Armelle Logié, Claire Dunois-Lardé, Christophe Rosty, Human Molecular Genetics	2005	175
Increased Levels of Insulin-Like Growth Factor II (IGF-II) and IGF-Binding Protein-2 Are Associated with Malignancy in Sporadic Adrenocortical Tumors<sup>1</sup> Nathalie Boulle, Armelle Logié, Christine Gicquel, The Journal of Clinical Endocrinology & Metabolism	1998	158
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity Nicola J. Curtis, Lorraine Mooney, Lorna Hopcroft, Oncotarget	2017	149
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models Sarah V. Holt, Armelle Logié, Rajesh Odedra, British Journal of Cancer	2012	111
Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line Armelle Logié, Nathalie Boulle, Véronique Gaston, Journal of Molecular Endocrinology Autocrine RoleGrowth HormoneCancer GrowthPathologyFibroblast Growth Factor	1999	105
Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055) Sarah V. Holt, Armelle Logié, Barry R. Davies, Cancer Research Dual Mtorc1Mtor Kinase InhibitorsMedicineMitogen-activated Protein KinaseApoptosis	2012	83
Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors Barry R. Davies, Nin Guan, Armelle Logié, Molecular Cancer Therapeutics	2015	70
High Expression of Cyclin E and G1 CDK and Loss of Function of p57<sup>KIP2</sup>Are Involved in Proliferation of Malignant Sporadic Adrenocortical Tumors<sup>1</sup> Nathalie Bourcigaux, Véronique Gaston, Armelle Logié, The Journal of Clinical Endocrinology & Metabolism Tumor BiologyRadiation OncologyG1 CdkHigh ExpressionPathology	2000	57

Page 1